BioMarin Pharmaceutical Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioMarin Pharmaceutical Inc. on January 29, 2026. The filing discloses a significant capital raise and debt restructuring intended to fund the pending acquisition of Amicus Therapeutics, Inc. (Amicus).
Key Financial Metrics and Capital Structure
- Debt Issuance: BioMarin entered into an agreement to sell $850 million of 5.500% senior unsecured notes due 2034.
- Debt Syndication: Completed syndication of a new $2 billion senior secured term loan "B" facility.
- Existing/Planned Facilities: The Term Loan B is in addition to an existing $800 million senior secured term loan "A" facility and a planned $600 million senior secured revolving credit facility.
- Use of Proceeds: Net proceeds from the notes, borrowings under the term facilities, and cash on hand will fund the Amicus acquisition consideration, related fees, and the new revolving facility.
- Interest Terms: The new notes accrue interest at 5.500% annually, payable semiannually starting August 15, 2026.
Material Changes and Transaction Details
The filing represents a material change in the company's capital structure to support a major M&A transaction. Key structural details include:
- Escrow Arrangement: Gross proceeds from the $850 million note issuance will be deposited into an escrow account pending the closing of the Amicus acquisition.
- Mandatory Redemption: If the acquisition is not completed by December 19, 2026, or upon certain other events, BioMarin must redeem all notes at 100% of the initial issue price plus accrued interest.
- Guarantees: The notes are jointly and severally guaranteed by certain subsidiaries, including Amicus and its subsidiaries post-acquisition.
- Ranking: The notes rank equal with existing unsubordinated indebtedness and senior to future subordinated debt, but are structurally subordinated to liabilities of non-guarantor subsidiaries.
Outlook, Risks, and Contingencies
Management expects the offering to close on or about February 12, 2026. The filing highlights several risks and contingencies:
- Transaction Risk: The capital raise is contingent on the successful consummation of the Amicus acquisition. Failure to close by the specified date triggers mandatory redemption of the notes.
- Covenants: The indenture includes customary covenants restricting additional debt, dividends, asset dispositions, and mergers.
- Change of Control: Holders have the right to require repurchase at 101% of principal plus accrued interest in the event of a change of control.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements regarding the timing and closing of these transactions.
Investor Verification Checklist
- Verify the final closing date of the Amicus Therapeutics acquisition to assess the mandatory redemption risk for the new notes.
- Confirm the final terms of the $600 million revolving credit facility and the $2 billion Term Loan B facility.
- Review the "Risk Factors" section in BioMarin's most recent Form 10-Q (quarter ended September 30, 2025) for updated risks related to the acquisition and debt load.
- Monitor the status of the escrow account holding the $850 million in note proceeds.
- Assess the impact of the new 5.500% interest rate on future cash flow and earnings.